Oxcarbazepine, Serum or Plasma

CPT: 80183
Print Share


  • GP 47680
  • Trileptal®

Test Includes

Analysis of active metabolite, 10-hydroxy carbamazepine (MHD)

Expected Turnaround Time

2 - 4 days

Related Documents

Specimen Requirements


Serum or plasma


1 mL

Minimum Volume

0.3 mL


Red-top tube, lavender-top (EDTA) tube, or green-top (heparin) tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.


Transfer separated serum or plasma to a plastic transport tube.

Storage Instructions

Maintain specimen at room temperature.

Stability Requirements



Room temperature

14 days


14 days


105 days

Freeze/thaw cycles

Stable x3

Causes for Rejection

Gross lipemia; hemolysis; icteric specimen; gel-barrier tube

Test Details


Oxcarbazepine is an antiepileptic drug, indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy. It is used in adjunctive therapy in epileptic children between the ages of four and 16.


Clinically significant hyponatremia (sodium <125 mmol/L) can develop during oxcarbazepine use. This generally occurs during the first three months of treatment.

This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.


Liquid chromatography/tandem mass spectrometry (LC/MS-MS)

Reference Interval

10−35 μg/mL

Additional Information

Oxcarbazepine is the prodrug for its active metabolite, 10-hydroxy-carbamazepine (MHD). MHD reaches maximal serum concentrations in three to five hours after oral ingestion and is 40% bound to protein. The elimination half-life is 8 to 15 hours.1 Co-administration of other antiepileptic drugs (eg, carbamazepine, phenytoin, phenobarbital, primidone) causes decreases in MHD serum levels.2


1. Bourgeois BF. Pharmacokinetic properties of current antiepileptic drugs. What improvements are needed? Neurology. 2000; 55(Suppl 3):S11-S16. 11147563
2. Wheless JW. Using the new antiepilepsy drugs in children. J Child Neurol. 2002 Jan; 17(Suppl 1):S58-S64. 11918465


Lensmeyer GL, Gidal BE, Wiebe DA. Optimized high-performance liquid chromatographic method for determination of lamotrigine in serum with concomitant determination of phenytoin, carbamazepine, and carbamazepine epoxide. Ther Drug Monit. 1997 Jun; 19(3):292-300. 9200770
Physicians' Desk Reference. 66th ed. Montvale, NJ: Thompson PDR; 2012.
Souppart C, Decherf M, Humbert H, Maurer G. Development of a high throughput 96-well plate sample preparation method for the determination of Trileptal (oxcarbazepine) and its metabolites in human plasma. J Chromatogr B Biomed Sci Appl. 2001 Oct 5; 762(1):9-15. 11589463


Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
716928 Oxcarbazepine (Trileptal),S 35331-8 716930 Oxcarbazepine ug/mL 35331-8

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf